Surein Arulananda

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Erinna F. Lee, Tiffany J. Harris, Sharon Tran et al. · Cell Death and Disease · 2019 · 186 citations · Full text

Medicine, Oncology, Pharmacology +17

Rheumatic immune-related adverse events secondary to anti–programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series

Emma L. Mitchell, Peter K. H. Lau, Chloe Khoo et al. · European Journal of Cancer · 2018 · 93 citations

Life Sciences, Immunology, Oncology +17

<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>

Jason D. Lickliter, Hui Gan, Mark Voskoboynik et al. · Drug Design Development and Therapy · 2020 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

Surein Arulananda, Megan A. O’Brien, Marco Evangelista et al. · Cell Death Discovery · 2021 · 35 citations · Full text

Medicine, Oncology, Pharmacology +15

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso

Nicholas McNamee, Catriona Harvey, Lauren Gray et al. · Journal of Thoracic Oncology · 2023 · 33 citations · Full text

Medicine, Immunology, Oncology +14